<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The epidermal growth factor receptor (EGFR) is an excellent candidate for targeted therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have demonstrated that apart from <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS, a <z:mp ids='MP_0002169'>wild-type</z:mp> BRAF and NRAS genotype is required for response to anti-EGFR therapy </plain></SENT>
<SENT sid="2" pm="."><plain>This suggests that NRAS and BRAF genotype criteria should be used together with KRAS genotype to select patients who will likely benefit from anti-EGFR therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the prevalence of mutations in the KRAS, BRAF and NRAS genes and its correlation with demographic characteristics, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location and stage in 100 colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients from India </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency of KRAS, BRAF and NRAS mutations was found to be 23%, 17% and 2.0%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>There was no significant difference in KRAS, NRAS and BRAF mutation with respect to gender, age, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location (colon vs rectum) and clinicopathological stage </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, we found a novel point variant (T20I) of unknown significance in NRAS exon 1 in addition to a KRAS codon 12 mutation in one of the rectal <z:mp ids='MP_0002038'>carcinoma</z:mp> patients </plain></SENT>
<SENT sid="7" pm="."><plain>In the present study, combined evaluation of genetic biomarkers (KRAS, NRAS and BRAF) was able to classify 42% of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients as likely non-responders to anti-EGFR therapy </plain></SENT>
</text></document>